BD1 charting, page-56

Well I think it’s pretty obvious why I won’t be asking your first question. Can you be more specific with your second question? From my understanding this is the third priority in the product pipeline and research is still underway.

One thing I’ve found about talking to company representatives is that you must try and think ahead from responses they might give you, which can become very difficult as we start trying to understand the technical aspects of a product in development. However if you can anticipate a response before the call then you can ask a question of deeper substance to try and understand a particular product or service better. I think you’re trying to find out timing, which is never certain and a vague question, rather than how the vaccine actually works or what risks are involved throughout the process.